|
Market Closed -
Nasdaq
23:00:00 24/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.9550 USD | +0.43% |
|
+1.49% | +37.87% |
| 08-18 | Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. | CI |
| 08-14 | Elutia Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 42.11M 36.09M 33.76M 30.87M 58.25M 4.03B 58.87M 400M 155M 2.02B 158M 155M 6.7B | P/E 2026 * |
-1.51x | P/E 2027 * | -1.76x |
|---|---|---|---|---|---|
| Enterprise Value | 42.11M 36.09M 33.76M 30.87M 58.25M 4.03B 58.87M 400M 155M 2.02B 158M 155M 6.7B | EV / Sales 2026 * |
5.62x | EV / Sales 2027 * | 9.79x |
| Free-Float |
85.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Elutia Inc.
| 1 day | +0.43% | ||
| 1 week | +1.49% | ||
| Current month | +11.46% | ||
| 1 month | +2.41% | ||
| 3 months | -17.67% | ||
| 6 months | -14.73% | ||
| Current year | +37.87% |
| 1 week | 0.88 |  | 0.99 |
| 1 month | 0.76 | | 1 |
| Current year | 0.6 | | 1.38 |
| 1 year | 0.5 | | 2.5 |
| 3 years | 0.5 | | 5.24 |
| 5 years | 0.5 | | 9.76 |
| 10 years | 0.5 | | 18.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | 52 | - | |
Charles Mills
CEO | Chief Executive Officer | 54 | 21/06/2022 |
Matthew Ferguson
DFI | Director of Finance/CFO | 58 | 28/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Rakin
CHM | Chairman | 65 | 01/11/2015 |
Charles Mills
BRD | Director/Board Member | 54 | 01/11/2015 |
Brigid Makes
BRD | Director/Board Member | 70 | 01/09/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 1/30/26 A | HighCape Partners Management LLC
| Other | Company | 0 | 0% | |
| 1/30/26 A | Buy | Director | 20,000 | 0.0496% | ||
| 1/30/26 A | Buy | Founder | 70,000 | 0.1735% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.43% | +1.49% | -54.31% | -32.27% | 42.11M | |
| -0.66% | +3.11% | +40.55% | -1.46% | 83.28B | |
| -4.30% | +119.35% | +412.13% | +20.29% | 57.94B | |
| +0.48% | +23.89% | -21.93% | -35.75% | 57.77B | |
| +1.42% | +1.61% | -0.67% | +34.08% | 51.75B | |
| -0.77% | +3.63% | +11.51% | +167.84% | 49.35B | |
| +0.62% | +3.95% | +56.57% | -17.63% | 32.03B | |
| +0.13% | +6.51% | +50.49% | +97.96% | 25.91B | |
| -2.83% | +6.08% | +0.05% | +223.58% | 22.74B | |
| -1.74% | +2.63% | +55.54% | +107.34% | 16.87B | |
| Average | -0.68% | +18.78% | +54.99% | +56.40% | 39.77B | |
| Weighted average by Cap. | -0.72% | +25.31% | +76.89% | +45.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.5M 6.43M 6.01M 5.5M 10.37M 718M 10.48M 71.15M 27.67M 361M 28.16M 27.55M 1.19B | 4.3M 3.69M 3.45M 3.15M 5.95M 412M 6.01M 40.79M 15.86M 207M 16.15M 15.8M 684M |
| Net income | -27.3M -23.4M -21.89M -20.01M -37.76M -2.61B -38.16M -259M -101M -1.31B -103M -100M -4.34B | -23.6M -20.23M -18.92M -17.3M -32.64M -2.26B -32.99M -224M -87.06M -1.13B -88.61M -86.69M -3.75B |
| Net Debt | - | - |
Employees
26
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/08/26 | $0.9550 | +0.43% | 7,995 |
| 21/08/26 | $0.9509 | +5.44% | 8,215 |
| 20/08/26 | $0.9018 | -2.32% | 47,930 |
| 19/08/26 | $0.9232 | +1.45% | 44,673 |
| 18/08/26 | $0.9100 | -6.75% | 58,353 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9509USD
Average target price
5.000USD
Spread / Average Target
+425.82%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ELUT Stock
Select your edition
All financial news and data tailored to specific country editions
